Skip to main content

Advertisement

Table 1 Characteristic of the included studies in the meta-analysis

From: Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis

Author Type of study Study period Country Number of patients Age (Mean ± SD) (Range) Gender (M/F) Smoking Follow-up, Months (Mean ± SD) Outcomes indexs Complication
Salvi M et al. 2007 [14] Cohort study NA Italy 9 44.8 ± 2.1 (31–51) 2/7 5 1 CAS, TRAbs, proptosis 3 nose and throat itching,mild temperature elevation
Vannucchi G et al. 2010 [17] Cohort study NA Italy 10 46.6 ± 2.2 (31–54) 2/8 NA 12 TRAbs, IL-6 NA
Silkiss RZ et al. 2010 [16] Cohort study 2007.1–2010.10 United States 12 52.1 (34–80) 5/7 4 12 CAS, TSH No
Khanna D et al. 2010 [15] Cohort study 2007.10.1–2009.2.1 United States 6 54.3 ± 9.1 2/4 3 7.5 ± 6.4 CAS, proptosis 1 urinary tract infection;1 hypertension;1 cardiac arrest
Mitchell AL et al. 2013 [18] Cohort study 2008–2012 UK 9 62 (37–87) 1/8 NA 16 CAS 2 headache;1 headache and chills without pyrexia;1 mild myalgia
Savino G et al. 2013 [19] Cohort study NA Italy 5 48 ± 12.1 3/2 3 18 CAS, proptosis 2 nausea and temperature elevation
Erdei A et al. 2014 Cohort study NA Hungary 5 47.8 ± 12.2 (31–64) 1/4 4 60 CAS, TRAbs, TSH NA
McCoy AN et al. 2014 [21] Cohort study 2007.10.1-? United States 8 57 ± 6.63 3/5 4 18 CAS NA
Stan MN et al. 2015 [23] Randomized controlled trial NA United States 13 57.6 ± 12.7 4/9 2 13 CAS, TRAbs, proptosis 2 myalgias;2 skin rash and itching);1 infectious;1 vasculitis;2 optic neuropathy;1 severe lacrimation;2 gastrointestinal;
Salvi M et al. 2015 [22] Randomized controlled trial NA Italy 15 51.9 ± 13.1 1/14 10 19 CAS, TRAbs, TSH, proptosis 1 orbital edema and decrease of vision;1 hypotension;1 myocardial infarction
Li J et al. 2017 [24] Randomized controlled trial NA China 75 48.1 ± 10.0 25/50 15 10 CAS, proptosis, IL-6 1 flushing;9 nose and throat itching;2 dyspepsia;9 temperature elevation
  1. NA not available